Abstract
Human arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) are polymorphic phase II xenobioticmetabolising enzymes (XME) that acetylate arylamine compounds. They therefore play an important role in the detoxication and / or metabolic activation of certain therapeutic drugs, occupational chemicals and carcinogens. Although the use of the term “xenobiotic” implies that XME form a separate and distinct class of enzymes, possible endogenous substrates may exist. Unlike NAT2, NAT1 is produced in most tissues. Polymorphism at the NAT1 locus has been associated with the existence of at least 26 allelic variants, generating phenotypic variations in terms of NAT1 catalytic activity. This genetic variation affects the acetylator status of individuals, leading to interindividual differences in drug response and predisposition to disease in humans. Recent studies have shown that non-genetic factors may also regulate NAT1 activity at the posttranslational level, with potentially important consequences for drug toxicity. In this minireview, we summarise what is currently known about the regulation of NAT1 activity by non-genetic factors, including substrates and oxidative stress. Recent findings presented here may account for the genotype / phenotype relationship for the NAT1 locus being less clear-cut than that for human NAT2.
Keywords: n-acetyltransferase, xenobiotics, polymorphism, catalytic activity, regulation, inherited factors, oxidative stress, enzyme inactivation
Current Pharmaceutical Design
Title: Regulation of the Activity of the Human Drug Metabolizing Enzyme Arylamine N-Acetyltransferase 1: Role of Genetic and Non Genetic Factors
Volume: 10 Issue: 20
Author(s): Fernando Rodrigues-Lima and Jean-Marie Dupret
Affiliation:
Keywords: n-acetyltransferase, xenobiotics, polymorphism, catalytic activity, regulation, inherited factors, oxidative stress, enzyme inactivation
Abstract: Human arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) are polymorphic phase II xenobioticmetabolising enzymes (XME) that acetylate arylamine compounds. They therefore play an important role in the detoxication and / or metabolic activation of certain therapeutic drugs, occupational chemicals and carcinogens. Although the use of the term “xenobiotic” implies that XME form a separate and distinct class of enzymes, possible endogenous substrates may exist. Unlike NAT2, NAT1 is produced in most tissues. Polymorphism at the NAT1 locus has been associated with the existence of at least 26 allelic variants, generating phenotypic variations in terms of NAT1 catalytic activity. This genetic variation affects the acetylator status of individuals, leading to interindividual differences in drug response and predisposition to disease in humans. Recent studies have shown that non-genetic factors may also regulate NAT1 activity at the posttranslational level, with potentially important consequences for drug toxicity. In this minireview, we summarise what is currently known about the regulation of NAT1 activity by non-genetic factors, including substrates and oxidative stress. Recent findings presented here may account for the genotype / phenotype relationship for the NAT1 locus being less clear-cut than that for human NAT2.
Export Options
About this article
Cite this article as:
Rodrigues-Lima Fernando and Dupret Jean-Marie, Regulation of the Activity of the Human Drug Metabolizing Enzyme Arylamine N-Acetyltransferase 1: Role of Genetic and Non Genetic Factors, Current Pharmaceutical Design 2004; 10 (20) . https://dx.doi.org/10.2174/1381612043383845
DOI https://dx.doi.org/10.2174/1381612043383845 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Modulation of Renin-Angiotensin System and Arterial Stiffness: Evidence from Clinical Trials
Current Hypertension Reviews Neuronal Histamine and its Receptors: Implication of the Pharmacological Treatment of Obesity
Current Medicinal Chemistry Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Autoimmune Polyendocrine Syndrome Complicated by Pulmonary Hypertension
Endocrine, Metabolic & Immune Disorders - Drug Targets Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus
Current Neurovascular Research Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Editorial [Hot topic: Sleep Abnormalities in Pulmonary Disease (Guest Editor: Shyamsunder Subramanian)]
Current Respiratory Medicine Reviews Functional Upregulation of STIM-1/Orai-1-Mediated Store-Operated Ca2+ Contributing to the Hypertension Development Elicited by Chronic EtOH Consumption
Current Vascular Pharmacology Nebivolol: More Than a Highly Selective Beta Blocker
Recent Patents on Cardiovascular Drug Discovery Depression Rises the Risk of Hypertension Incidence: Discussing the Link through the Ca2+/cAMP Signalling
Current Hypertension Reviews Development of a Novel Nanocomposite Based on Reduced Graphene Oxide/Chitosan/Au/ZnO and Electrochemical Sensor for Determination of Losartan
Current Analytical Chemistry Diabetic Cardiomyopathy: Electromechanical Cellular Alterations
Current Vascular Pharmacology Insights into the Regulation of Renal Hemodynamic Function in Diabetic Mellitus
Current Diabetes Reviews Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Use of Contrast Echocardiography in Intensive Care and at the Emergency Room
Current Cardiology Reviews New Developments In Treatment After Lung Transplantation
Current Pharmaceutical Design